May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Potentiation of Topical Voriconazole (VCZ) Ocular Penetration by Pretreatment with Topical Latanoprost (LT)
Author Affiliations & Notes
  • D.T. Dang
    Univ of TX Hlth Sci Ctr at San A, San Antonio, TX, United States
  • R.D. Glickman
    Univ of TX Hlth Sci Ctr at San A, San Antonio, TX, United States
  • J.R. Graybill
    Univ of TX Hlth Sci Ctr at San A, San Antonio, TX, United States
  • W.E. Sponsel
    Univ of TX Hlth Sci Ctr at San A, San Antonio, TX, United States
  • A. Miller
    Univ of TX Hlth Sci Ctr at San A, San Antonio, TX, United States
  • R. Melendez
    Univ of TX Hlth Sci Ctr at San A, San Antonio, TX, United States
  • M. Pena
    Univ of TX Hlth Sci Ctr at San A, San Antonio, TX, United States
  • Y. Trigo
    Univ of TX Hlth Sci Ctr at San A, San Antonio, TX, United States
  • H.A. Reitsamer
    Univ of TX Hlth Sci Ctr at San A, San Antonio, TX, United States
  • Footnotes
    Commercial Relationships  D.T. Dang, None; R.D. Glickman, Pfizer Central Research I; J.R. Graybill, Pfizer Central Research C; W.E. Sponsel, Pfizer Central Research F; A. Miller, None; R. Melendez, None; M. Pena, None; Y. Trigo, None; H.A. Reitsamer, None.
  • Footnotes
    Support  Pfizer Central Research, Odyssey Ophthalmic, Inc.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 4275. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D.T. Dang, R.D. Glickman, J.R. Graybill, W.E. Sponsel, A. Miller, R. Melendez, M. Pena, Y. Trigo, H.A. Reitsamer; Potentiation of Topical Voriconazole (VCZ) Ocular Penetration by Pretreatment with Topical Latanoprost (LT) . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4275.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the potential enhancement of intraocular penetration of voriconazole (triazole; Pfizer) using the PGF2-alpha analogue latanoprost (Xalatan; Pharmacia & Upjohn). Methods: Seven New Zealand White (NZW) rabbits were divided into two groups. In the control group, two NZW rabbits were given a single topical dose of 5ug/ml VCZ topical suspension OU, without any pretreatment. In the experimental group, five NZW rabbits were pre-treated with one drop of LT (50ug/ml) OD and a drop of saline OS for six days. On day six, the rabbits were given a single dose of 5ug/ml VCZ topical suspension OD only. Aqueous and vitreous samples were obtained from all eyes at 120 minutes or at 210 minutes following VCZ administration. The content of VCZ was measured by liquid chromatography-mass spectrometry (LC-MS: Thermoquest LCQ). Results: VCZ application time did not materially affect the findings, and the data were combined for analysis. In the control (no LT pretreatment) group, the mean concentration of VCZ in the aqueous was 343.7 ng/ml (range 124.0-930.2), and in the vitreous was 20.3 ng/ml in one animal and <LOQ (limit of quantitation) in the others. In the experimental (LT pretreated) group, the mean VCZ concentration in the aqueous was 319 ng/ml (range 155.6-479.1), and in the vitreous was 86.2 ng/ml (range 24.8-169.2). In the non-pretreated left eyes that received only saline, VCZ aqueous concentration was measured at 17.1 and 45.1 ng/ml in two eyes, respectively, and <LOQ in the others, while in the vitreous VCZ was <LOQ in all eyes. Conclusion: LT pretreatment did not affect the penetration of VCZ into the aqueous, but significantly enhanced the penetration of VCZ into the vitreous compartment (p~.014, Bonferroni multiple comparison test), which otherwise was not accessible solely by topical application.

Keywords: antibiotics/antifungals/antiparasitics • vitreous • pharmacology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×